Brain Trust Accelerator Fund

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Myavana, previously known as Madame You, is a company that specializes in personalized hair care solutions. It utilizes a combination of artificial intelligence and expertise from hair care professionals to assist women in managing their hair. The company offers a mobile application that provides scientific, data-driven analysis of individual hair types and textures. Through this platform, users receive tailored recommendations for hair products and styling techniques that best suit their unique needs. Myavana aims to empower individuals by enhancing their hair care routines with customized guidance.

Chase Therapeutics is an early-stage specialty pharmaceutical company dedicated to developing innovative treatments for brain diseases. The company focuses on creating novel compounds that address both symptomatic relief and disease modification. By employing advanced approaches, Chase Therapeutics aims to enhance the quality of life for individuals suffering from central nervous system disorders. Its commitment to improving therapeutic options positions the company as a key player in the pharmaceutical landscape for brain disease treatment.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Chase Pharmaceuticals Corporation is a specialty pharmaceutical company established in 2007 and headquartered in Washington, D.C. The company is dedicated to developing innovative medications aimed at treating Alzheimer's disease and related neurodegenerative disorders. Its primary product, CPC-252, is a transdermal formulation designed for managing the symptoms of Alzheimer's and Parkinsonism dementia. Chase Pharmaceuticals focuses on identifying and advancing promising treatments for central nervous system diseases, with a goal of addressing the significant unmet medical need in neuropsychiatry, particularly with Alzheimer’s disease, which is recognized as a major public health challenge. The company operates by selecting and developing product candidates that can be licensed to commercial partners, thus contributing to its strategic aim of improving the quality of life for those affected by cognitive decline. With an increasing global population affected by Alzheimer's and escalating healthcare costs, Chase Pharmaceuticals is positioned to play a crucial role in the development of more effective therapies for this condition.

Satoris specializes in the development of neurodiagnostic tests aimed at identifying neurological diseases, including Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is dedicated to creating tests that provide early, accurate, and clinically relevant diagnoses. By focusing on the convenience and affordability of these tests, Satoris aims to enhance patient care while simultaneously reducing healthcare costs.